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ABSTRACT
Despite prompt reperfusion by primary percutaneous
coronary intervention (PPCI), the mortality and morbidity
of patients presenting with an acute ST-segment
elevation myocardial infarction (STEMI) remain signiﬁcant
with 9% death and 10% heart failure at 1 year. In these
patients, one important neglected therapeutic target is
‘myocardial reperfusion injury’, a term given to the
cardiomyocyte death and microvascular dysfunction
which occurs on reperfusing ischaemic myocardium. A
number of cardioprotective therapies (both mechanical
and pharmacological), which are known to target
myocardial reperfusion injury, have been shown to
reduce myocardial infarct (MI) size in small proof-of-
concept clinical studies—however, being able to
demonstrate improved clinical outcomes has been
elusive. In this article, we review the challenges facing
clinical cardioprotection research, and highlight future
therapies for reducing MI size and preventing heart
failure in patients presenting with STEMI at risk of
myocardial reperfusion injury.
INTRODUCTION
For patients presenting with an acute ST-segment
elevation myocardial infarction (STEMI), the most
effective therapy for reducing myocardial infarct
(MI) size, preserving LV systolic function and
preventing the onset of heart failure, is timely
reperfusion by primary percutaneous coronary
intervention (PPCI). Although, myocardial reperfu-
sion is a pre-requisite to salvaging viable myocar-
dium, the process of restoring coronary blood ﬂow
can paradoxically induce myocardial injury and
cardiomyocyte death, thereby mitigating the full
beneﬁts of reperfusion in terms of MI size reduc-
tion—a phenomenon which has been termed ‘myo-
cardial reperfusion injury’.1 2 The fact that a
therapeutic intervention administered solely at the
time of myocardial reperfusion can reduce MI size
by up to half suggests that myocardial reperfusion
injury may account for up to 50% of the ﬁnal MI
size.1 Although, the process of myocardial reperfu-
sion has been optimised by advances in stent tech-
nology, new antiplatelet drugs (eg, prasugrel,
ticagrelor and abciximab) and novel antithrombotic
agents (eg, bivalirudin therapy), the latter being
provided to maintain the rheology of blood ﬂow,
there is still no effective therapy for preventing
myocardial reperfusion injury in PPCI patients.
Following a STEMI, the size of the resultant myo-
cardial infarct has been strongly linked with the
development of adverse LV remodelling and heart
failure,3 and subsequent prognosis following
PPCI.4 Larose et al5 have shown that an MI size of
≥23% LV volume was associated with a HR of 6
for major adverse cardiac events.
In this article, we review the challenges facing
clinical cardioprotection research, and highlight
future opportunities for reducing MI size and
improving clinical outcomes in patients presenting
with STEMI at risk of myocardial reperfusion
injury.
CHALLENGES FACING CLINICAL
CARDIOPROTECTION RESEARCH
There are a number of challenges facing clinical
cardioprotection research. First, the translation of
novel cardioprotective therapies into the clinical
setting for patient beneﬁt has been extremely difﬁ-
cult. Extensive literature exists on the complex
array of prosurvival signalling pathways which
underlie cardioprotection, and the readers are
referred to a number of recent reviews6 7—in
ﬁgure 1, a simpliﬁed overview is provided which
illustrates some of the major prosurvival pathways
which mediate cardioprotection at the time of
reperfusion. These have provided researchers with
a number of molecular targets for pharmacological
targeting of myocardial reperfusion injury. Over
the past 30–40 years, a vast number of therapies
with proven efﬁcacy for preventing myocardial
reperfusion injury and reducing MI size in experi-
mental animal studies (eg, antioxidants, magne-
sium, calcium-channel blockers, anti-inﬂammatory
agents, erythropoietin, atorvastatin, glucose-insulin-
potassium therapy, adenosine) have produced
disappointing results when investigated in the clin-
ical setting as adjunctive therapy to reperfusion
(reviewed in Ref. 9). More recently, a number of
attempts to reduce MI size in patients presenting
with STEMI have also failed to meet their primary
end point of cardioprotection—these have included
studies investigating therapeutic hypothermia, tar-
geting mitochondrial function, and modulation of
nitric oxide signalling as adjuncts to myocardial
reperfusion (table 1 and ﬁgure 1).
The reasons for this failure to translate cardio-
protection into the clinical setting have been attrib-
uted to a number of factors including the use of
inappropriate animal MI models and poorly
designed clinical studies—a topic which has been
discussed extensively in the literature and is high-
lighted in a following section.9 17
A second challenge facing clinical cardioprotec-
tion research is that clinical outcomes of patients
presenting with STEMI following PPCI continue to
improve, making it increasingly difﬁcult to demon-
strate a reduction in MI size and improvement in
clinical outcomes with a novel cardioprotective
therapy. However, although mortality following
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STEMI is in decline, the number of patients surviving STEMI
and going on to develop heart failure is increasing. There
remains, therefore, an unmet need to discover novel therapeutic
strategies capable of preventing myocardial reperfusion injury
and reducing MI size, so as to preserve LV systolic function and
prevent the onset of heart failure in patients presenting with
reperfused STEMI. In the next section and in tables 2 and 3 we
highlight a number of therapeutic strategies, which hold
promise for reducing MI size and improving clinical outcomes
in patients presenting with reperfused STEMI.
POTENTIAL THERAPIES FOR REDUCING MI SIZE
Ischaemic postconditioning: interrupting myocardial
reperfusion to limit MI size
Interrupting myocardial reperfusion with several short-lived epi-
sodes of myocardial ischaemia has been demonstrated in experi-
mental animal studies to prevent myocardial reperfusion injury
and reduce MI size—a phenomenon which has been termed
‘ischaemic postconditioning’ (IPost).40 This therapeutic approach
was rapidly translated into the clinical setting by Staat et al,27
who demonstrated that IPost (using four 1-min low-pressure
inﬂations and deﬂations of the angioplasty balloon following
direct stenting of the culprit lesion) led to a 36% reduction in MI
size in PPCI-treated patients presenting with STEMI. Although a
number of subsequent studies have reported similar beneﬁcial
ﬁndings with IPost, there have been a substantial number of
neutral studies29 30 (table 3). The reasons for this are unclear but
it appears that most beneﬁt is obtained in patients with anterior
STEMI presenting with a completely occluded artery (TIMI
0).29 28 Furthermore, the IPost protocol is best delivered follow-
ing direct stenting and upstream of the stent rather than within it.
Whether IPost can improve long-term clinical outcomes is not
known, and is currently being investigated in the ongoing Danish
Study of Optimal Acute Treatment of Patients with ST-Elevation
Myocardial Infarction (DANAMI-3) trial.31
Natriuretic peptide
Experimental animal studies have found that administering
atrial natriuretic peptide (ANP) prior to myocardial reperfusion
can reduce MI size through the activation of known prosurvival
signalling pathways.41 Kitakaze et al18 translated this therapeutic
approach in a large clinical study comprising 569 patients pre-
senting with STEMI, in which administering Carperitide (an
ANP analogue) at the time of PPCI was associated with a 14.7%
reduction in enzymatic MI size (table 2). Further studies are
required to conﬁrm these ﬁndings and investigate whether this
therapeutic approach can improve clinical outcomes in patients
presenting with reperfused STEMI.
Ciclosporin-A: targeting the mitochondrial permeability
transition pore
The opening of the mitochondrial permeability transition pore
(MPTP) in the ﬁrst minutes of reperfusion is a critical mediator
of reperfusion-induced cardiomyocyte death, and preventing its
opening using pharmacological inhibitors of the MPTP such as
ciclosporin-A (CsA) has been reported in experimental studies
to limit MI size.42 The ﬁrst study to translate this therapeutic
approach into the clinical setting was by Piot et al19 who found
Figure 1 This scheme depicts the main prosurvival signalling pathways underlying ischaemic conditioning and the potential sites of actions for
novel therapies which have recently been investigated in clinical studies to reduce myocardial infarct (MI) size in reperfused ST-segment elevation MI
(STEMI) patients (please see tables 1–3, for details on the novel therapies and their potential sites of actions). The orange boxes indicate those
therapies which have had mainly neutral effects on MI size and/or clinical outcomes (table 1) and the yellow boxes indicate those therapies which
have the potential to improve clinical outcomes in reperfused patients presenting with STEMI (table 2). The signalling cascade underlying
cardioprotection begins at the cardiomyocyte plasma membrane with the activation of G-protein coupled or cytokine receptors by autocoids such as
adenosine, bradykinin or opioids (released in response to the ischaemic conditioning stimulus)—this results in the recruitment of signalling
pathways such as the Reperfusion Injury Salvage Kinase (phosphatidylinositol 3-kinase-Akt (PI3K-Akt) and Mitogen-activated protein kinase kinase
1/2 -Extracellular signal-Regulated Kinase 1/2 (MEK1/2-Erk1/2)), Survivor Activator Factor Enhancement (SAFE), Janus kinase and Signal Transducer
and Activator of Transcription (JAK-STAT) and the PKG pathways. These salvage pathways have been shown to activate downstream mediators such
as endothelial Nitric Oxide Synthase (eNOS), Glycogen Synthase Kinase 3 Beta (GSK-3β), Hexokinase II (HKII), Protein Kinase C-epsilon (PKC-ε), the
mitochondrial ATP-dependent potassium channel (KATP) which then mediate an inhibitory effect on mitochondrial permeability transition pore
(MPTP) opening (adapted from Ref. 8).
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in a small study of 58 patients presenting with STEMI that
administering a single intravenous (IV) bolus of CsA prior to
PPCI reduced MI size by approximately 40% as measured by cre-
atine kinase (CK) (table 2). The recently completed
CYCLosporinE A in Reperfused Acute Myocardial Infarction
(CYCLE) study investigated the effect of MPTP inhibition using
CsA (Sandimmune preparation) on ST-segment resolution, and
the results of this study are eagerly awaited (table 2). Rather sur-
prisingly, the large randomised Cyclosporine and Prognosis in
Acute Myocardial Infarction Patients (CIRCUS) Phase III trial
(comprising 791 patients presenting with acute anterior STEMI
with data on the primary end point), which investigated the
effect of CsA as an adjunct to PPCI on long-term clinical out-
comes, failed to show any beneﬁcial effect on the primary com-
bined end point of all-cause mortality, hospitalisation for heart
failure and adverse LV remodelling at 1 year21 (table 2). The
reason for this neutral result is not clear—whether it relates to
the Ciclomulsion preparation used in the study or failure of the
drug to reach its target is not clear.2 Should MPTP inhibition
ever be implemented as a therapeutic approach into the clinical
setting, novel, more speciﬁc MPTP inhibitors will be needed,
given the potential side effects and off-target effects of CsA.
Table 1 Recent attempts to reduce MI size in reperfused patients presenting with STEMI
Clinical study
Therapeutic intervention
(patient population) N Main outcomes
Mechanism of cardioprotection
potential reasons for neutral results
Therapeutic hypothermia
Erlinge et al10
CHILL-MI
IV 600 to 2000 mL cold saline and
endovascular cooling prior to PPCI
for 1h to cool to 34.7°C
120 No effect on primary end point
of MI size (CMR at 4 days)
Delays reperfusion by 9 min
Experimental studies show that mild hypothermia, induced before
reperfusion reduced MI size.
The reasons for the neutral study are unclear but may relate to:
20%–27% of patients had TIMI flow of > 0 before PPCI
Only 76% of patients had a temperature of <35°C at reperfusion
Interestingly, post-hoc sub-group analysis revealed that patients
presenting early (<4 h) with anterior STEMI had a smaller
MI/AAR
Nichol et al11
VELOCITY
Peritoneal hypothermia to cool to
34.7°C
57 No effect on primary end point
of MI size (CMR at 3–5 days)
Delays reperfusion by 15 min
Increase in stent thrombosis
The reasons for the neutral study may relate to:
▸ The study being underpowered.
▸ Out of 26 patients in the hypothermia arm, 6 had TIMI flow
of >1 prior to PPCI and <50% achieved a temperature of
<34.9°C at the time of PPCI
Targeting mitochondrial function
Lincoff et al12
PROTECTION-AMI
IV delcasertib infusion for 2.5 h
(LAD/RCA STEMI)
1010 No effect on primary end point
of AUC CK-MB
Peptide inhibitor of delta-protein kinase C a major mediator of
the mitochondrial apoptotic pathway which has been reported in
animal studies to reduce MI size when administered prior to
reperfusion.The reasons for the neutral study is unclear but may
relate to:
▸ 30%–40% of patients had TIMI flow of >1 before PPCI.
▸ Intravenous delcasertib may take up to 30 min to reach
steady state and therefore may not have been effective at
reperfusion
▸ Lack of signs of toxicity raised the question of whether the
dose used was sufficient
Atar et al13
MITOCARE
IV bolus of TRO40303 prior to
angioplasty
(All-comer STEMI, TIMI <1)
163 No effect on primary end point
of 72 h AUC CK-MB/Troponin-T
This drug is an indirect inhibitor of the mitochondrial permeability
transition pore which has been reported in animal studies to
reduce MI size when administered prior to reperfusion.The reason
for the neutral study is unclear but may relate to:
▸ Relatively small MI size compared with previous studies
▸ Groups were not well balanced (higher initial mean CK, less
patients with TIMI 0 pre-PPCI and more patients with TIMI 0/
1 post PPCI, older age by 4 years in the TR040303 group)
▸ Concerns that the dose used may not have been correct
Chakrabarti et al14
EMBRACE-STEMI
IV infusion (75 min) of Bendavia
started 15 min before reperfusion
(LAD STEMI, TIMI 0)
118 No effect on the primary end
point of 72 h AUC CK-MB
A mitochondria-targeting peptide which has been reported in
animal studies to reduce MI size when administered prior to
reperfusion.
The reason for the neutral study is unclear but may be because
the study was underpowered. Full study results are awaited.
Nitric oxide signalling
Siddiqi et al15
(NIAMI)
IV sodium nitrite (70 mmol) over 5
min prior to PPCI
(All-comer STEMI, TIMI<1)
229 No effect on the primary end
point of 72 h AUC CK-MB
The reason for the neutral study is unclear but may relate to the
route of drug administration and the fact that >90% of patient
had received GTN prior to reperfusion
Jones et al16 NITRITE IC sodium nitrite (1.8 μmol) bolus
prior to angioplasty
(All-comer STEMI)
80 No effect on the primary end
point of MI size (as % LV
mass) (on 6–8 days CMR)
The reason for the neutral study is unclear but may relate to
patient selection as post-hoc subgroup analysis revealed reduced
MI size in patients with LAD STEMI
NOMI
NCT01398384
Inhaled nitric oxide at 80 ppm for
4 h initiated prior to PPCI
248 No effect on the primary end
point of MI size (as % of LV
mass) on CMR (48–72 h)
The reason for the neutral study is unclear but may relate to
patient selection (post-hoc subgroup analysis revealed reduced MI
size in patients with LAD STEMI) and prior dosing with IC/IV GTN
as patients who were GTN-naïve, there was a reduction in MI size
AUC, area under curve; CK-MB, creatine kinase myocardial band; CMR, cardiovascular MRI; GTN, glyceryl trinitrate; IC, intracoronary; IV, intravenous; LAD, left anterior descending
artery; MI, myocardial infract; PPCI, primary percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction; TIMI, Thrombolysis in MI.
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Exenatide: lizard saliva and cardioprotection
Exenatide (Byetta), a synthetic version of exendin-4 (a peptide
isolated from the saliva of the Gila lizard), is a long-acting ana-
logue of glucagon-like peptide-1 (GLP-1), a hormone which
lowers blood glucose by stimulating insulin secretion.43
Interestingly, GLP-1 and its analogues such as exenatide have
been reported in experimental animal studies to reduce MI size
through the activation of prosurvival intracellular signalling
pathways when administered prior to reperfusion.44 45
Lonborg et al23 showed that initiating a 6 h infusion of exena-
tide prior to PPCI reduced MI size by 30% as measured by car-
diovascular magnetic resonance (CMR) in patients presenting
with STEMI, and most beneﬁt was seen in those patients pre-
senting <132 min from ﬁrst medical contact.22 Woo et al24 also
showed a signiﬁcant reduction in MI size by CMR (26.4
±11.6 g in the placebo arm vs 12.8±11.7 g in the exenatide
arm: p<0.01) in 58 patients with subcutaneous exenatide
(table 2). Whether this effect of exenatide portends to improved
clinical outcomes in patients presenting with reperfused STEMI
is not known and remains to be determined in a large rando-
mised clinical trial.
Remote ischaemic conditioning: transient limb ischaemia/
reperfusion
Inducing brief non-lethal episodes of ischaemia and reperfusion
in the arm or leg, using serial inﬂations and deﬂations (three
to four 5 min cycles) of a standard blood pressure cuff placed
on the upper arm or thigh, has been shown to protect the
Table 2 Potential pharmacological strategies for reducing MI size and improving clinical outcomes in patients presenting with reperfused
STEMI
Clinical study
Therapeutic intervention
(patient population) N Main outcomes
Mechanism of cardioprotection and other
comments
Atrial natriuretic peptide
Kitakaze et al18 IV Carperitide (atrial natriuretic
peptide analogue) 72 h infusion
started prior to PPCI
(All-comer STEMI)
569 15% reduction in MI size (72 h AUC total CK)
2.0% absolute increase in LVEF
Atrial natriuretic peptide targets prosurvival kinase
pathways such as the cGMP and RISK pathways
Ciclosporin A
Piot et al19 20 IV Ciclosporin A (2.5 mg/kg
Sandimmune) bolus 10 min
prior to PPCI
(LAD/RCA STEMI, TIMI 0)
58 44% reduction in MI size (72 h AUC total CK)
20% reduction in MI size (CMR subset)
28% reduction in MI size and smaller LVESV on CMR at
6 months
Ciclosporin A inhibits the opening of the
mitochondrial permeability transition pore, a
critical determinant of lethal myocardial
reperfusion injury
Cung et al21
CIRCUS
IV Ciclosporin A (2.5 mg/kg
Ciclomulsion) bolus 10 min
prior to PPCI
(LAD STEMI, TIMI 0)
791 No effect on the primary end point at 1 year of all-cause
mortality, rehospitalisation for heart failure and adverse
LV remodelling by echocardiography (59.0% Ciclosporin
A vs 58.1% Control)
The reason for the neutral study is unclear but
may relate to the Ciclomulsion preparation or
failure of the drug to reach its molecular target. .
CYCLE
NCT01650662
IV Ciclosporin-A (2.5 mg/kg
Sandimmune) bolus 5 min prior
to PPCI
(LAD STEMI, TIMI 0/1)
410 Ongoing study
Primary end point of ST-segment resolution ≥70% 1 h
after PPCI
Recruitment complete October 2014—results
awaited
CAPRI
NCT02390674
IV Ciclosporin-A (2.5 mg/kg
Sandimmune) bolus prior to
PPCI
(All-comer STEMI)
68 Ongoing study
Primary end point MI size (3 month CMR)
Exenatide
Lonborg
et al22 23
IV infusion of Exenatide started
15 min prior to PPCI and
continued for 6 h
(All-comer STEMI, TIMI 0/1)
105 23% reduction in MI size (3 month CMR)
Increase in myocardial salvage index (0.62–0.71)
Short ischaemic times (≤132 minutes) associated with
greater myocardial salvage
Exenatide, a GLP-1 analogue, targets prosurvival
kinase pathways such as the RISK pathway
Woo et al24 S/C injection of Exenatide prior
to PPCI
(All-comer STEMI, TIMI 0)
58 52% reduction in MI size (1 month CMR)
27% reduction in MI size (72 h AUC CK-MB)
54% reduction in MI size (72 h AUC Trop-I)
EMPRES
NCT01938235
IV infusion of Exenatide for
24 h
(All-comer STEMI, TIMI 0/1)
198 Ongoing study
Primary end point of MI size at 3 months over
area-at-risk at 72 h post randomisation (using CMR)
Metoprolol
Ibanez et al25 26 IV Metoprolol (3×5 mg) in
ambulance prior to PPCI
(LAD STEMI)
270 20% reduction in MI size (7 day CMR)
3.7% absolute increase in LVEF (6 months CMR)
59% reduction in the incidence of poor LVEF (<35%)
(6 months CMR)
65% reduction in need for ICD by 65% at 6 months
68% reduction in HHF at 2 years
The mechanism of cardioprotection is not clear.
Roovlink et al
EARLY BAMI
IV Metoprolol (3×5 mg) in
ambulance prior to PPCI
(LAD STEMI)
408 Ongoing study
Primary end point of MI size at 30 days on CMR
Ongoing study selecting patients with STEMI
presenting within 12 h of onset of symptoms
AUC, area under curve; cGMP, cyclic guanosine monophosphate; CK, creatine kinase; CK-MB, creatine kinase myocardial band; CMR, cardiovascular magnetic resonance; GLP-1,
glucagon-like peptide-1; HHF, hospitalisation for heart failure; ICD, implantable cardiac defibrillator; ICD, implantable cardiac defibrillator; IV, intravenous; LAD, left anterior descending
artery; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; LVESV, left ventricular end-systolic volume; MI, myocardial infarct; PPCI, primary percutaneous
coronary intervention; RCA, right coronary artery; RISK, reperfusion injury salvage kinase; STEMI, ST-segment elevation myocardial infarction; S/C, subcutaneous; TIA, transient ischaemic
attack; TIMI, Thrombolysis in Myocardial infarction; Trop, troponin.
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heart against acute ischaemia-reperfusion injury (IRI)—a
phenomenon known as ‘remote ischaemic conditioning’
(RIC).46–48 It has been suggested that a blood-borne factor, of
as yet unknown identity, is generated in response to the limb
RIC stimulus, and this then transfers the cardioprotective
stimulus from the limb to the heart where prosurvival
Table 3 Potential mechanical strategies for reducing MI size and improving clinical outcomes in patients presenting with reperfused STEMI
Clinical study
Therapeutic intervention/patient
characteristics N Main outcomes Comments
Ischaemic postconditioning (major studies only)
Staat et al27 4×1 min angioplasty balloon
inflations/deflations
(All comer STEMI, TIMI 0)
30 36% reduction in MI size (72 h AUC Total CK) First study to demonstrate reduction in MI
size with IPost
Thibault et al28 4×1 min angioplasty balloon
inflations/deflations
(All comer STEMI, TIMI 0)
38 39% reduction in MI size (6 months SPECT)
7% absolute increase in LVEF at 12 months
First study to demonstrate long-term
cardioprotection with IPost
Sorensson et al29 4×1-min angioplasty balloon
inflations/deflations
(All comer STEMI, TIMI 0)
76 No difference in MI size overall
However, reduction in MI size in patients with large
AAR
Hahn et al30 4×1 min angioplasty balloon
inflations/deflations
(All comer STEMI, TIMI 0)
700 No difference in the primary end point of complete
ST-segment resolution at 30 min post-PPCI
Largest neutral study with IPost.
IPost performed at site of culprit lesion and
MI size not measured.
Hofsten et al
DANAMI-331
4×0.5 min angioplasty balloon
inflations/deflations
(All comer STEMI, TIMI 0/1)
2000 Ongoing study
Primary end point of all-cause mortality and heart
failure at 2 years
Recruitment complete and follow-up in
process
Results due
First study to investigate the effect of IPost on
long-term clinical outcomes
Remote ischaemic conditioning
Botker et al32 4×5 min arm cuff inflations/
deflations in the ambulance prior to
PPCI
(All comer STEMI)
142 Increase in myocardial salvage index at 30 days
No difference in MI size (SPECT or peak Trop-I)
First study to test effect of RIC in PPCI-treated
patients presenting with STEMI. Reduced MI
size in LAD STEMI.
Rentoukas et al33 4×4 min arm cuff inflations/
deflations at the hospital prior to
PPCI
(All comer STEMI)
93 Better ST segment resolution and lower peak Trop-I.
Synergistic effects with morphine
Crimi et al34 3×5-min thigh cuff inflations/
deflations at onset of reperfusion by
PPCI
(LAD STEMI)
100 20% reduction in MI size (72 h AUC CK-MB) First study to show benefit with RIC started at
onset of reperfusion
White et al35
ERIC-STEMI
4×5 min arm cuff inflations/
deflations at the hospital prior to
PPCI
(All comer STEMI)
197 27% reduction in MI size (acute CMR)
Sloth et al36 4×5 min upper arm cuff inflations/
deflations in the ambulance prior to
PPCI
(All comer STEMI)
251 51% reduction in composite end point of all-cause
mortality, non-fatal MI, TIA or stroke, HHF at
3.8 years
First study to show an effect of RIC on
long-term outcomes following PPCI
(secondary end point)
Prunier et al37
RIPOST-MI
4×5 min arm cuff inflations/
deflations at hospital prior to PPCI
with or without IPost
(All comer STEMI)
151 No difference in reduction in enzymatic MI size
(CK-MB) with RIC vs RIC+IPost (31% vs 19%)
First study to test the effect of a combined
therapeutic approach with RIC and IPost
Yellon et al38
ERIC-LYSIS
4×5 min arm cuff inflations/
deflations at hospital prior to
thrombolysis
(All comer STEMI)
519 19% reduction in enzymatic MI size (CK-MB)
32% reduction in enzymatic MI size (Trop-T)
First study to test the effect of RIC in patients
presenting with thrombolysed STEMI
Eitel et al39 5
LIPSIA
3×5 min arm cuff inflations/
deflations at hospital prior to PPCI
with IPost
(All comer STEMI)
696 Increased myocardial salvage index (CMR at 3 days)
with RIC+IPost when compared with control (49
(IQR 30–72) vs 40 (IQR 16–68), p=0.02)
Largest study to test the effect of a combined
therapeutic approach with RIC and IPost
No beneficial effect with IPost alone
RIC-STEMI
NCT02313961
3×5 min thigh cuff inflations/
deflations prior to PPCI
(All comer STEMI)
492 Ongoing study
Primary end point of cardiac death and HHF at
12 months
CONDI-2/ERIC-PPCI
(NCT02342522)
(NCT01857414)
4×5 min arm cuff inflations/
deflations prior to PPCI
(All comer STEMI)
4300 Ongoing study
Primary end point of cardiac death and HHF at
12 months
Collaboration between UK, Denmark and
Spain
First study to investigate effect of RIC on
long-term outcomes following PPCI
AAR, area-at-risk; AUC, area under curve; CK, creatine kinase; CK-MB, creatine kinase MB isoenzyme; CMR, cardiovascular magnetic resonance; HHF, hospitalisation for heart failure;
IPost, Ischaemic postconditioning; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction; MI, myocardial infarct; PPCI, primary percutaneous coronary intervention;
RIC, remote ischaemic conditioning; SPECT, single-photon emission CT; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic attack; TIMI, Thrombolysis in
Myocardial infarction; Trop, Troponin.
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intracellular signalling pathways are then activated and confer
cardioprotection.48
A number of proof-of-concept clinical studies have demon-
strated MI size reduction using limb RIC in patients presenting
with STEMI treated by either PPCI32–34 37 39 49 50 and by
thrombolysis38 (table 3). Whether this simple, non-invasive,
low-cost, non-pharmacological intervention can improve long-
term clinical outcomes in this patient group is currently being
investigated in the Effect of RIC on Clinical Outcomes in
STEMI Patients Undergoing PPCI and the Effect of Remote
Ischaemic Conditioning on Clinical Outcomes in STEMI
Patients Undergoing PPCI (CONDI2/ERIC-PPCI) trial. This
European multicentre (Denmark, UK and Spain) randomised
clinical trial of 4300 patients presenting with STEMI will deter-
mine whether upper limb RIC applied prior to PPCI can reduce
the rate of cardiac death and heart failure hospitalisation at
1 year (ClinicalTrials.gov Identiﬁers: NCT02342522 and
NCT01857414).
Repeated RIC post MI has attracted attention as a potential
chronic cardioprotective therapy. Wei et al51 demonstrated in
the rat heart that daily limb RIC for 28 days prevented adverse
post-MI LV remodelling. The Chronic Remote Ischemic
Conditioning to Modify Post-MI Remodeling (CRIC-RCT,
NCT01817114) study and the Daily Remote Ischaemic
Conditioning following Acute Myocardial Infarction (DREAM,
NCT01664611) study are currently investigating this thera-
peutic strategy (daily RIC for 1 month) on post-MI LV remodel-
ling following PPCI.
Metoprolol: β-blockers and MI size reduction
Whether early β-blocker therapy is beneﬁcial in patients present-
ing with reperfused STEMI is controversial and had not previ-
ously been investigated in the PPCI era. Using a porcine mode
of acute myocardial IRI, Ibanez et al52 demonstrated that IV
metoprolol administered prior to reperfusion resulted in a ﬁve-
fold increase in myocardial salvage. The same researchers went
on to apply this therapeutic strategy in the clinical setting by
demonstrating that IV metoprolol administered in the ambu-
lance prior to PPCI reduced MI size by 20% (assessed by
CMR)52 and improved clinical outcomes in patients presenting
with STEMI (as a secondary end point)25 26 (table 2). Whether
this pharmacological approach to reducing MI size can improve
clinical outcomes will need to be tested in a large prospectively
powered randomised controlled clinical trial.
Combination reperfusion therapy: a novel therapeutic
strategy
Prior attempts to reduce MI size in patients presenting with
STEMI have relied on targeting one single component of myo-
cardial reperfusion injury with a single agent. Whether, using
combination reperfusion therapy can provide more effective car-
dioprotection against myocardial reperfusion injury remains to
be investigated. In this regard, Alburquerque-Bejar et al53 have
recently demonstrated an additive 26% reduction in MI size
when combining RIC with insulin-like therapies (such as
glucose-insulin-potassium and exenatide) in a porcine acute MI
model. The Combination Therapy in Myocardial Infarction
(COMBAT-MI) study (ClinicalTrials.gov Identiﬁer:
NCT02404376) will investigate the potential beneﬁts of com-
bined reperfusion therapy using RIC with exenatide on MI size
reduction in patients presenting with STEMI treated by PPCI.
Although an initial clinical study of 54 patients in patients pre-
senting with reperfused STEMI failed to show an additive cardi-
oprotective effect with RIC and IPost administered in
combination,37 a recently published larger study of 696 patients
found increased myocardial salvage in those patients adminis-
tered RIC in combination with IPost when compared with con-
trols (49 (IQR 30–72) vs 40 (IQR 16–68), p=0.02)39 (table 3).
OPTIMISING THE CLINICAL TRANSLATION OF
CARDIOPROTECTION
There are number of factors which need to be taken into con-
sideration when designing clinical cardioprotection studies for
reducing MI size in patients presenting with reperfused STEMI,
as this may help facilitate the translation of novel cardioprotec-
tive therapies into the clinical setting for patient beneﬁt.9
▸ Patient selection—where possible, consider selecting those
patients presenting with STEMI who are most likely to
beneﬁt from the novel cardioprotective therapy—those pre-
senting: early (<2–3 h as shown by Lonborg et al22 and
Garcia-Dorado et al54); with a large area-at-risk (>30% of
the LV volume)29 and an occluded artery prior to PPCI
(TIMI <1) may be more likely to beneﬁt from adjunctive
therapy for reducing MI size. However, restricting patient
selection has to be balanced with conﬁning the testing of the
novel cardioprotective therapy to a smaller selected group of
patients.
▸ The cardioprotective therapy—consider only testing those
novel therapies which have shown conclusive cardioprotec-
tion in a number of experimental small and large animal MI
studies. In this regard, the NIH CESAR network in the USA
offers the opportunity to test the cardioprotective efﬁcacy of
novel therapies in a multicentre small and large animal
model setting akin to a multicentre clinical trial.55 Similarly,
where possible it is important to demonstrate that the novel
cardioprotective therapy is efﬁcacious in several different
clinical studies before proceeding to testing it in clinical out-
comes studies.
▸ Confounders of cardioprotection—the presence of certain
comorbidities (such as age, diabetes, pre-existing coronary
artery disease, heart failure, hypertension, dyslipidaemia) and
concomitant medication (nitrates, morphine, nicorandil, sul-
fonylureas, platelet inhibitors) may interfere with the efﬁcacy
of the novel cardioprotective therapy.56 Where possible this
should be taken into consideration when designing experi-
mental or clinical cardioprotection studies.
▸ Timing of the cardioprotective therapy—as myocardial reper-
fusion injury manifests in the ﬁrst minutes of reperfusion, it
is essential that the novel cardioprotective therapy is adminis-
tered prior to myocardial reperfusion if it is to be effective.
A number of neutral clinical studies were due to administer-
ing the cardioprotective therapy after reperfusion had
already taken place.
▸ Study end points—consider selecting study end points which
are most likely to be affected by the novel cardioprotective
therapy—these include surrogate end points such as MI size
(enzymatic, myocardial single-photon emission CT or CMR),
myocardial salvage index (which is more sensitive than MI
size reduction but requires the assessment of the AAR);
microvascular obstruction (coronary no-reﬂow, index of
microcirculatory resistance, or CMR), LV size and function
and hard clinical end point such as heart failure hospitalisa-
tion, and cardiac death.
FUTURE PERSPECTIVES
Clinical cardioprotection research remains a challenge—mortal-
ity rates following a PPCI-treated STEMI are in decline, which
makes demonstrating a further reduction in MI size and
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improved clinical outcomes increasingly more difﬁcult.
However, an increasing number of patients are developing heart
failure—as such, novel cardioprotective therapies which target
myocardial reperfusion injury and reduce MI size provide the
opportunity to preserve LV systolic function and prevent the
onset of heart failure. The failure to translate a large number of
infarct-limiting therapies into the clinical setting should not be
taken as evidence that myocardial reperfusion injury does not
exist in humans. Rather, it should provide the impetus to opti-
mise the design of our experimental animal and clinical studies,
and improve how we select which novel cardioprotective
therapy to test in the clinical setting—this may hopefully facili-
tate the discovery of new effective therapies for reducing MI
size and preventing heart failure in patients presenting with
reperfused STEMI. Initial data suggest that using a combination
of therapies to target myocardial reperfusion injury may be
more beneﬁcial than using a single therapy approach, and using
this approach may result in improved clinical outcomes in this
patient group.
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